Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#101 / 200 Total
TRVI - Trevi Therapeutics Inc - Stock Price Chart
TickerTRVI [NASD, RUT]
CompanyTrevi Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap185.96MEPS (ttm)-0.34
P/E-EPS this Y-44.83%
Forward P/E-EPS next Y-10.00%
PEG-EPS past 5Y27.24%
P/S-EPS next 5Y-
P/B2.52EPS Q/Q-68.88%
Dividend-Sales Q/Q-
Insider Own33.43%Inst Own41.16%
Insider Trans0.00%Inst Trans43.28%
Short Float1.92%EarningsMay 07/a
Analyst Recom1.00Target Price7.40
Avg Volume300.65K52W Range0.97 - 4.00
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Delfini LisaChief Financial OfficerOct 11 '23Option Exercise0.512,2921,17136,686Oct 12 04:00 PM
Delfini LisaChief Financial OfficerOct 11 '23Sale2.027851,58635,901Oct 12 04:00 PM
Delfini LisaChief Financial OfficerSep 11 '23Option Exercise0.512,2911,17135,105Sep 13 04:06 PM
Delfini LisaChief Financial OfficerSep 11 '23Sale2.207111,56434,394Sep 13 04:06 PM
Delfini LisaChief Financial OfficerAug 11 '23Option Exercise0.512,2921,17133,496Aug 14 04:00 PM
ACRS - Aclaris Therapeutics Inc - Stock Price Chart
TickerACRS [NASD, RUT]
CompanyAclaris Therapeutics Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap86.94MEPS (ttm)-1.09
P/E-EPS this Y35.87%
Forward P/E-EPS next Y22.78%
PEG-EPS past 5Y20.67%
P/S2.79EPS next 5Y-
P/B0.61EPS Q/Q43.39%
Dividend-Sales Q/Q-5.14%
Insider Own9.10%Inst Own87.17%
Insider Trans0.22%Inst Trans0.40%
Short Float7.71%EarningsMay 07/a
Analyst Recom2.78Target Price1.84
Avg Volume1.02M52W Range0.59 - 11.12
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powell Andrew Kenneth WilliamDirectorMar 04 '24Buy1.256,0007,50028,863Mar 05 04:58 PM
Powell Andrew Kenneth WilliamDirectorMar 01 '24Buy1.238,50010,45522,863Mar 05 04:58 PM
Monahan JosephChief Scientific OfficerOct 23 '23Sale5.086,00030,460129,724Oct 25 04:28 PM
Balthaser KevinChief Financial OfficerSep 06 '23Buy7.909,49074,97115,461Sep 07 04:16 PM
Loerop JamesChief Business OfficerAug 28 '23Buy6.8014,70599,95921,688Aug 28 04:39 PM
JOBY - Joby Aviation Inc - Stock Price Chart
TickerJOBY [NYSE, RUT]
CompanyJoby Aviation Inc
CountryUSA
IndustryAirports & Air Services
Market Cap3.46BEPS (ttm)-0.75
P/E-EPS this Y6.31%
Forward P/E-EPS next Y-5.47%
PEG-EPS past 5Y-
P/S3259.97EPS next 5Y-11.81%
P/B3.54EPS Q/Q25.99%
Dividend-Sales Q/Q-
Insider Own46.86%Inst Own30.99%
Insider Trans-0.55%Inst Trans0.23%
Short Float20.46%EarningsMay 07/a
Analyst Recom2.33Target Price8.00
Avg Volume5.07M52W Range4.25 - 11.98
Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeHoff KateSee RemarksMay 03 '24Sale5.5012,50068,750184,567May 07 06:39 PM
Papadopoulos DidierPresident of Aircraft OEMMay 03 '24Sale5.502,58714,22873,697May 07 06:39 PM
Simi Bonny WPresident of OperationsApr 29 '24Option Exercise1.7756,581100,148205,147May 01 04:08 PM
Papadopoulos DidierPresident of Aircraft OEMApr 18 '24Sale4.646,09128,26276,284Apr 18 06:58 PM
Bevirt JoeBenCEO and Chief ArchitectApr 18 '24Sale4.645,44825,279662,605Apr 18 06:58 PM
KRNT - Kornit Digital Ltd - Stock Price Chart
TickerKRNT [NASD]
CompanyKornit Digital Ltd
CountryIsrael
IndustrySpecialty Industrial Machinery
Market Cap724.69MEPS (ttm)-1.21
P/E-EPS this Y128.97%
Forward P/E43.37EPS next Y187.67%
PEG-EPS past 5Y-
P/S3.55EPS next 5Y-2.80%
P/B0.91EPS Q/Q26.96%
Dividend-Sales Q/Q-8.38%
Insider Own0.18%Inst Own97.03%
Insider Trans0.00%Inst Trans2.20%
Short Float1.64%EarningsMay 08/b
Analyst Recom1.33Target Price24.20
Avg Volume430.42K52W Range13.29 - 31.94
Kornit Digital Ltd. is engaged in the development, designing, manufacture, and marketing of industrial and commercial printing solutions for the garment, apparel, and textile industries. It offers printing solutions for apparel, polyester, sportswear, beachwear, accessories, paradigm shirt, textiles, curtains, cushions and couches. The company was founded by Ofer Ben-Zur on January 16, 2002 and is headquartered in Rosh HaAyin, Israel.
PRPL - Purple Innovation Inc - Stock Price Chart
TickerPRPL [NASD, RUT]
CompanyPurple Innovation Inc
CountryUSA
IndustryFurnishings, Fixtures & Appliances
Market Cap164.44MEPS (ttm)-1.35
P/E-EPS this Y36.64%
Forward P/E-EPS next Y56.43%
PEG-EPS past 5Y-17.83%
P/S0.31EPS next 5Y15.00%
P/B2.51EPS Q/Q-100.00%
Dividend-Sales Q/Q9.75%
Insider Own6.92%Inst Own76.69%
Insider Trans0.05%Inst Trans-7.95%
Short Float4.25%EarningsMay 07/a
Analyst Recom2.25Target Price2.75
Avg Volume783.27K52W Range0.55 - 3.78
Purple Innovation, Inc. engages in the design and manufacture of comfort technology products. It offers mattresses, bed pillows, seat cushions, mattress protector, and bamboo sheets. The company was founded by Terry V. Pearce and Tony Marion Pearce in 1989 and is headquartered in Lehi, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ulrich George TurnerPrincipal Accounting OfficerMar 22 '24Buy1.524,0006,06116,874Mar 26 08:00 AM
DICAMILLO GARY TDirectorAug 28 '23Buy2.2210,00022,182158,478Aug 30 11:03 AM
McGarvey Casey KaleChief Legal OfficerJun 02 '23Buy2.8522,30063,553108,436Jun 06 04:10 PM
KERBY JEFFERY SCOTTChief of Owned RetailMay 26 '23Buy3.4516,35056,44539,427May 30 05:44 PM
DARLING SETH LANEDirectorMay 16 '23Buy3.0217,00051,42517,000May 16 08:35 PM
MRNS - Marinus Pharmaceuticals Inc - Stock Price Chart
TickerMRNS [NASD, RUT]
CompanyMarinus Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap78.14MEPS (ttm)-2.64
P/E-EPS this Y22.74%
Forward P/E-EPS next Y44.07%
PEG-EPS past 5Y6.04%
P/S2.76EPS next 5Y20.00%
P/B-EPS Q/Q-1.39%
Dividend-Sales Q/Q-26.02%
Insider Own6.40%Inst Own101.68%
Insider Trans-0.62%Inst Trans1.35%
Short Float8.83%EarningsMay 08/b
Analyst Recom1.55Target Price6.67
Avg Volume1.91M52W Range1.11 - 11.26
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Braunstein ScottCHAIRMAN AND CEOMar 27 '24Option Exercise4.2850,000214,000273,512Mar 27 11:55 AM
Shafer ChristinaCHIEF COMMERCIAL OFFICERFeb 20 '24Sale9.562,15320,58360,308Feb 22 04:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Feb 20 '24Sale9.571,89418,12652,966Feb 22 04:05 PM
Braunstein ScottCHAIRMAN AND CEOFeb 16 '24Sale9.9411,850117,789223,512Feb 21 04:05 PM
Pfanstiel StevenCFO AND COOFeb 16 '24Sale9.973,09230,82771,697Feb 21 04:05 PM
ARDX - Ardelyx Inc - Stock Price Chart
TickerARDX [NASD, RUT]
CompanyArdelyx Inc
CountryUSA
IndustryBiotechnology
Market Cap1.98BEPS (ttm)-0.29
P/E-EPS this Y-22.55%
Forward P/E69.82EPS next Y133.03%
PEG-EPS past 5Y28.61%
P/S12.47EPS next 5Y30.00%
P/B13.15EPS Q/Q11.99%
Dividend-Sales Q/Q304.81%
Insider Own3.86%Inst Own58.74%
Insider Trans-7.17%Inst Trans51.39%
Short Float15.08%EarningsMay 02/a
Analyst Recom1.00Target Price13.83
Avg Volume6.07M52W Range3.16 - 10.13
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williams Laura AChief Medical OfficerMay 03 '24Option Exercise0.9930,00029,700410,138May 07 04:48 PM
GRAMMER ELIZABETH ASee RemarksMay 03 '24Sale9.0045,000405,000267,993May 07 06:24 PM
Williams Laura AChief Medical OfficerMay 03 '24Sale8.3539,949333,574370,189May 07 04:48 PM
RAAB MICHAELPresident & CEOApr 29 '24Option Exercise0.9930,00029,7001,340,933May 01 07:59 PM
RAAB MICHAELPresident & CEOApr 29 '24Sale6.4030,000192,0571,310,933May 01 07:59 PM
IPSC - Century Therapeutics Inc - Stock Price Chart
TickerIPSC [NASD, RUT]
CompanyCentury Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap254.35MEPS (ttm)-2.30
P/E-EPS this Y11.11%
Forward P/E-EPS next Y8.02%
PEG-EPS past 5Y15.24%
P/S114.06EPS next 5Y-
P/B1.00EPS Q/Q-21.14%
Dividend-Sales Q/Q-48.56%
Insider Own62.32%Inst Own23.58%
Insider Trans-0.14%Inst Trans-1.48%
Short Float5.55%EarningsMar 14/b
Analyst Recom1.33Target Price14.40
Avg Volume197.65K52W Range1.28 - 5.51
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Russotti GregorySee RemarksMay 06 '24Sale3.125,00015,619292,319May 07 05:13 PM
Farid AdrienneChief Operations OfficerMay 03 '24Sale3.119132,836137,236May 07 05:13 PM
Carr DouglasSVP Finance & OperationsMay 03 '24Sale3.11257798317,323May 07 05:13 PM
Russotti GregorySee RemarksApr 22 '24Sale3.105,00015,490297,319Apr 24 04:17 PM
Farid AdrienneChief Operations OfficerMar 07 '24Option Exercise1.0322,83123,516136,980Mar 08 06:29 PM
MAXN - Maxeon Solar Technologies Ltd - Stock Price Chart
TickerMAXN [NASD, RUT]
CompanyMaxeon Solar Technologies Ltd
CountrySingapore
IndustrySolar
Market Cap109.78MEPS (ttm)-5.35
P/E-EPS this Y45.55%
Forward P/E-EPS next Y6.46%
PEG-EPS past 5Y28.81%
P/S0.10EPS next 5Y-
P/B0.65EPS Q/Q-107.39%
Dividend-Sales Q/Q-29.21%
Insider Own40.93%Inst Own51.50%
Insider Trans0.00%Inst Trans0.42%
Short Float38.91%EarningsMay 15/a
Analyst Recom3.00Target Price5.00
Avg Volume2.35M52W Range1.71 - 38.91
Maxeon Solar Technologies Ltd. engages in the manufacturer and marketer of premium solar power technology. Its products include Maxeon Line of IBC solar cells and panels, and the Performance Line of shingled solar cells and panels. The firm owns and operates solar cell and panel manufacturing facilities located in France, Malaysia, Mexico and the Philippines, as well as participate in a joint venture in China with TZS. The company was founded in 2019 and is headquartered in Singapore.
AQST - Aquestive Therapeutics Inc - Stock Price Chart
TickerAQST [NASD]
CompanyAquestive Therapeutics Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap280.86MEPS (ttm)-0.43
P/E-EPS this Y-214.42%
Forward P/E-EPS next Y11.93%
PEG-EPS past 5Y46.61%
P/S5.45EPS next 5Y-
P/B-EPS Q/Q-259.47%
Dividend-Sales Q/Q8.25%
Insider Own11.31%Inst Own26.71%
Insider Trans-0.72%Inst Trans-3.13%
Short Float4.96%EarningsMay 07/a
Analyst Recom1.12Target Price9.00
Avg Volume2.86M52W Range1.25 - 6.23
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schobel Alexander MarkChief Innovation/Tech OfficerMar 15 '24Sale6.0050,000300,000984,476Mar 19 02:30 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMar 08 '24Sale5.1925,000129,6851,040,371Mar 12 01:45 PM
167891011121314151620